EA200970350A1 - Антагонисты ccr2 для лечения фиброза - Google Patents

Антагонисты ccr2 для лечения фиброза

Info

Publication number
EA200970350A1
EA200970350A1 EA200970350A EA200970350A EA200970350A1 EA 200970350 A1 EA200970350 A1 EA 200970350A1 EA 200970350 A EA200970350 A EA 200970350A EA 200970350 A EA200970350 A EA 200970350A EA 200970350 A1 EA200970350 A1 EA 200970350A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fibrosis
ccr2 antagonists
treatment
mcp
therapy
Prior art date
Application number
EA200970350A
Other languages
English (en)
Inventor
Анук Дас
Линн Мюррей
Фархат Саид
Original Assignee
Сентокор Орто Байотек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сентокор Орто Байотек, Инк. filed Critical Сентокор Орто Байотек, Инк.
Publication of EA200970350A1 publication Critical patent/EA200970350A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Терапию при помощи анти-МСР-1/CCR2 антагонистов предлагают для контроля или реверсирования заболеваний, связанных с фиброзом, включая, например, но не ограничиваясь ими, терапию антагонистами MCP-1/CCR2 для модуляции профиброзных маркеров, связанных с фиброзными процессами, включающими отложение пучков коллагена и альвеолярный коллапс.
EA200970350A 2006-10-05 2007-10-05 Антагонисты ccr2 для лечения фиброза EA200970350A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82825306P 2006-10-05 2006-10-05
PCT/US2007/080542 WO2008060783A2 (en) 2006-10-05 2007-10-05 Ccr2 antagonists for treatment of fibrosis

Publications (1)

Publication Number Publication Date
EA200970350A1 true EA200970350A1 (ru) 2009-12-30

Family

ID=39322434

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970350A EA200970350A1 (ru) 2006-10-05 2007-10-05 Антагонисты ccr2 для лечения фиброза

Country Status (17)

Country Link
US (1) US20100074886A1 (ru)
EP (1) EP2068920A2 (ru)
JP (1) JP2010505878A (ru)
KR (1) KR20090074787A (ru)
CN (1) CN101616689A (ru)
AU (1) AU2007319660A1 (ru)
BR (1) BRPI0718225A2 (ru)
CA (1) CA2665808A1 (ru)
CO (1) CO6160339A2 (ru)
EA (1) EA200970350A1 (ru)
EC (1) ECSP099226A (ru)
GT (1) GT200900075A (ru)
IL (1) IL198005A0 (ru)
MX (1) MX2009003762A (ru)
NI (1) NI200900048A (ru)
NO (1) NO20091630L (ru)
WO (1) WO2008060783A2 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20081785A1 (es) 2007-02-19 2009-01-12 Novartis Ag Derivados de ciclohexil-amida del acido aril carboxilico
RU2547595C2 (ru) 2008-08-18 2015-04-10 Пфайзер Инк Антитела против ccr2
US8465413B2 (en) 2010-11-25 2013-06-18 Coloplast A/S Method of treating Peyronie's disease
CN103391931A (zh) * 2011-02-25 2013-11-13 辉瑞有限公司 治疗肝纤维化的方法
WO2013148232A1 (en) * 2012-03-27 2013-10-03 Genentech, Inc. Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
AU2013266340A1 (en) * 2012-05-22 2014-12-04 Shire Human Genetic Therapies, Inc. Anti-CCL2 antibodies for treatment of scleroderma
EP2864358B1 (en) * 2012-06-22 2019-08-07 Sorrento Therapeutics, Inc. Antigen binding proteins that bind ccr2
CA2883711A1 (en) 2012-09-07 2014-03-13 The Governors Of The University Of Alberta Methods and compositions for diagnosis of inflammatory liver disease
US20170239262A1 (en) * 2014-03-21 2017-08-24 Tobira Therapeutics ,Inc. Cenicriviroc for the treatment of fibrosis
JP2019501965A (ja) * 2015-12-11 2019-01-24 ベロ バイオテック エルエルシー 一酸化窒素を含むガスを投与するための方法及び装置
JOP20190095A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
US20180193003A1 (en) 2016-12-07 2018-07-12 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP3554541B1 (en) 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
JP7034499B2 (ja) * 2017-06-27 2022-03-14 ニューラクル サイエンス カンパニー リミテッド 線維症の治療のための抗ｆａｍ１９ａ５抗体の用途
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9600820D0 (sv) * 1996-03-01 1996-03-01 Pharmacia Ab Antibodies and their use
GB9716657D0 (en) * 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
US6696550B2 (en) * 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US6312689B1 (en) * 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
NZ515374A (en) * 1999-05-18 2004-09-24 Teijin Ltd Remedies or prophylactics for diseases in association with chemokines
GB0016138D0 (en) * 2000-06-30 2000-08-23 Novartis Ag Organic compounds
AU2001292301A1 (en) * 2000-10-11 2002-04-22 Daiichi Pharmaceutical Co., Ltd. Novel drugs for liver diseases
US6670364B2 (en) * 2001-01-31 2003-12-30 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
CA2572289A1 (en) * 2004-06-30 2006-08-17 Centocor, Inc. Anti-mcp-1 antibodies, compositions, methods and uses
US8114964B2 (en) * 2005-05-19 2012-02-14 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses
WO2006125201A2 (en) * 2005-05-19 2006-11-23 Centocor, Inc. Anti-biotin-pegylated-mcp-1 mutein antibodies, compositions, methods and uses

Also Published As

Publication number Publication date
GT200900075A (es) 2010-05-14
NO20091630L (no) 2009-07-03
KR20090074787A (ko) 2009-07-07
EP2068920A2 (en) 2009-06-17
AU2007319660A1 (en) 2008-05-22
US20100074886A1 (en) 2010-03-25
BRPI0718225A2 (pt) 2013-11-12
MX2009003762A (es) 2009-07-10
IL198005A0 (en) 2011-08-01
CA2665808A1 (en) 2008-05-22
JP2010505878A (ja) 2010-02-25
NI200900048A (es) 2010-02-01
CN101616689A (zh) 2009-12-30
WO2008060783A2 (en) 2008-05-22
ECSP099226A (es) 2009-06-30
CO6160339A2 (es) 2010-05-20
WO2008060783A3 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
EA200970350A1 (ru) Антагонисты ccr2 для лечения фиброза
EA200602221A1 (ru) Новое применение пептидных соединений для лечения боли при тригеминальной невралгии
EA201070822A1 (ru) Доставка антител посредством модульного домена распознавания
EA201000559A1 (ru) Композиции и способы применения антител к склеростину
EA200971077A1 (ru) Гетероциклические модуляторы киназы
EA201001785A1 (ru) Модуляторы рецепторов сфингозин-1-фосфата
EA201100505A1 (ru) Органические соединения для применения для лечения бактериальных инфекций
DE502007002289D1 (de) Methacrylatharze zur herstellung von fahrbahnmarkierungen
NZ588033A (en) Methods of treating a mif-mediated disorder
PA8784101A1 (es) Oxazolidinonas sustituidas y su uso
EA200801220A1 (ru) 3-аминоциклопентанекарбоксамиды в качестве модуляторов хемокиновых рецепторов
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
EA201500403A1 (ru) Соединения, активирующие теломеразу, и способы их применения
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
ATE478856T1 (de) Spirobenzodioxole und deren verwendung als cb1- antagonisten
EA201171043A1 (ru) Композиции и способы длительной терапии с применением аминопиридинов
EA201101479A1 (ru) Новые p2x7r антагонисты и их применение
WO2008156685A3 (en) Tendon stem cells
ATE510536T1 (de) Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen
ECSP088939A (es) Carboxamidas sustituidas como antagonistas del receptor metabotropico del grupo i
EA201200855A1 (ru) Модуляторы crth2
ATE536368T1 (de) Konjugate von zytotoxischen verbindungen mit peptiden
DE502006001740D1 (de) Zusammensetzung zur Vorbeugung und Behandlung von Erkältungskrankheiten
CY1112443T1 (el) Νεα θεραπευτικη χρηση για τη θεραπεια των λευχαιμιων
BRPI0923892A2 (pt) tratamento com vapor d'água de uma poliolefina